adarx.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $505MM
ADARx Pharmaceuticals is a company that specializes in genetic medicine designed to treat human diseases and ailments using mRNA transcripts. ADARx researches and develops its therapies through oligonucleotides delivery technology. The firm focuses on three main disease treatments: genetic diseases, cardiometabolic diseases, and central nervous system (CNS) diseases.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
08/09/2023 | Series C | $200MM | $xx.xx | $827.77MM | Ascenta Capital, Bain Capital Life Sciences, Blackrock, Commodore Capital, Cormorant Asset Management, Hbm Healthcare Investments, Invus, Lilly Asia Ventures, Marshall Wace, Orbimed Advisors, Redmile Group, Sr One Capital Management, Tcgx, T. Rowe Price Associates, Venrock Healthcare Capital Partners, Vivo Capital | |
Price per Share
$xx.xx
Shares Outstanding
24,038,463
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ascenta Capital, Bain Capital Life Sciences, Blackrock, Commodore Capital, Cormorant Asset Management, Hbm Healthcare Investments, Invus, Lilly Asia Ventures, Marshall Wace, Orbimed Advisors, Redmile Group, Sr One Capital Management, Tcgx, T. Rowe Price Associates, Venrock Healthcare Capital Partners, Vivo Capital
|
||||||
01/20/2023 | Series B-1 | $46MM | $xx.xx | $484.32MM | Ascenta Capital, Lilly Asia Ventures, Orbimed Advisors, Sirona Capital, Sr One Capital Management | |
Price per Share
$xx.xx
Shares Outstanding
6,913,353
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ascenta Capital, Lilly Asia Ventures, Orbimed Advisors, Sirona Capital, Sr One Capital Management
|
||||||
09/08/2021 | Series B | $75MM | $xx.xx | $361.97MM | Lilly Asia Ventures, Orbimed Advisors, Sirona Capital, Sr One Capital Management | |
Price per Share
$xx.xx
Shares Outstanding
14,653,302
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Lilly Asia Ventures, Orbimed Advisors, Sirona Capital, Sr One Capital Management
|
||||||
05/14/2021 | Series A | $31.5MM | $xx.xx | $52.5MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
31,315,236
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|